Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
California Neuropsychopharmacology Clinical Research Institute (CNRI)
mi
from
San Diego, CA
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
California Neuropsychopharmacology Clinical Research Institute (CNRI)
mi
from
San Diego, CA
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
University of Colorado, Boulder
mi
from
Boulder, CO
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
mi
from
Boulder, CO
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Florida Clinical Research Center ,LLC,2468 USHWY 441/27,Suite#403
mi
from
Fruitland park, FL
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Florida Clinical Research Center ,LLC,2468 USHWY 441/27,Suite#403
mi
from
Fruitland park, FL
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Depression Clinical and Research Program
mi
from
Boston, MA
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Depression Clinical and Research Program
mi
from
Boston, MA
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Janus Center for Psychiatric Research
mi
from
West Palm Beach, FL
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Janus Center for Psychiatric Research
mi
from
West Palm Beach, FL
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
American Medical Research, Inc.
mi
from
Oak Brook, IL
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
American Medical Research, Inc.
mi
from
Oak Brook, IL
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340
mi
from
Lake Charles, LA
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340
mi
from
Lake Charles, LA
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Sheppard Pratt Health System
mi
from
Baltimore, MD
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Sheppard Pratt Health System
mi
from
Baltimore, MD
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Capitol Clinical Research
mi
from
Rockville, MD
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Capitol Clinical Research
mi
from
Rockville, MD
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Albuquerque Neuroscience Inc.
mi
from
Albuquerque, NM
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Albuquerque Neuroscience Inc.
mi
from
Albuquerque, NM
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Social Psychiatric Research Institute
mi
from
Brooklyn, NY
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Social Psychiatric Research Institute
mi
from
Brooklyn, NY
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Richard H. Weisler & Associates
mi
from
Raleigh, NC
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Richard H. Weisler & Associates
mi
from
Raleigh, NC
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Mood Disorders Program at University Hospitals of Cleveland
mi
from
Cleveland, OH
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Mood Disorders Program at University Hospitals of Cleveland
mi
from
Cleveland, OH
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Metro Health Medical Center
mi
from
Cleveland, OH
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
Metro Health Medical Center
mi
from
Cleveland, OH
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
FutureSearch Clinical Trials
mi
from
Austin, TX
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression
Status: Archived
Updated: 1/1/1970
FutureSearch Clinical Trials
mi
from
Austin, TX
The Efficacy of Parent Involvement in the Treatment of Adolescent Depression
The Efficacy of Parent Involvement in the Treatment of Adolescent Depression
Status: Archived
New York State Psychiatric Insitute
mi
from
New York, NY
The Efficacy of Parent Involvement in the Treatment of Adolescent Depression
The Efficacy of Parent Involvement in the Treatment of Adolescent Depression
Status: Archived
Updated: 1/1/1970
New York State Psychiatric Insitute
mi
from
New York, NY
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Pfizer Investigational Site
mi
from
Los Angeles, CA
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Los Angeles, CA
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Pfizer Investigational Site
mi
from
Arvada, CO
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Arvada, CO
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Pfizer Investigational Site
mi
from
Atlanta, GA
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Atlanta, GA
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Pfizer Investigational Site
mi
from
Bloomingdale, IL
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Bloomingdale, IL
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Pfizer Investigational Site
mi
from
Baltimore, MD
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Baltimore, MD
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Pfizer Investigational Site
mi
from
Akron, OH
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Akron, OH
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Pfizer Investigational Site
mi
from
Ashland, OR
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Ashland, OR
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Pfizer Investigational Site
mi
from
Houston, TX
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Houston, TX
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Pfizer Investigational Site
mi
from
Seattle, WA
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Seattle, WA
Using Cognitive Training to Improve Employment Programs for People With Severe Mental Illnesses
Cognitive Training to Improve Work Outcomes in Severe Mental Illness
Status: Archived
UC San Diego Medical Center
mi
from
San Diego, CA
Using Cognitive Training to Improve Employment Programs for People With Severe Mental Illnesses
Cognitive Training to Improve Work Outcomes in Severe Mental Illness
Status: Archived
Updated: 1/1/1970
UC San Diego Medical Center
mi
from
San Diego, CA
Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder
Imaging Serotonin 5-HT1A Receptors in the High Affinity State in Brains of Patients With Major Depressive Disorder
Status: Archived
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder
Imaging Serotonin 5-HT1A Receptors in the High Affinity State in Brains of Patients With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189
A Phase 1, Randomized, Subject Single Blinded, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of NSI-189 Phosphate in Healthy Subjects
Status: Archived
California Clinical Trials
mi
from
Glendale, CA
Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189
A Phase 1, Randomized, Subject Single Blinded, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of NSI-189 Phosphate in Healthy Subjects
Status: Archived
Updated: 1/1/1970
California Clinical Trials
mi
from
Glendale, CA
Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression
Ketamine Anesthesia to Enhance Efficacy and Tolerability of Electroconvulsive Therapy in Patients With Unipolar or Bipolar Depression
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression
Ketamine Anesthesia to Enhance Efficacy and Tolerability of Electroconvulsive Therapy in Patients With Unipolar or Bipolar Depression
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)
Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)
Status: Archived
Mayo Clinic Department of Psychiatry and Psychology
mi
from
Rochester, MN
Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)
Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)
Status: Archived
Updated: 1/1/1970
Mayo Clinic Department of Psychiatry and Psychology
mi
from
Rochester, MN
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
San Diego, CA
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Diego, CA
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Denver, CO
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Denver, CO
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Atlanta, GA
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Atlanta, GA
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Evanston, IL
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Evanston, IL
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Kansas City, KA
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Kansas City, KA
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Pascagoula, MS
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Pascagoula, MS
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Bronx, NY
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bronx, NY
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Akron, OH
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Akron, OH
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Bend, OR
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bend, OR
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Allentown, PA
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Allentown, PA
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Clinical Research Facility
mi
from
Bellingham, WA
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as Monotherapy Treatment in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bellingham, WA